SMAD2 and pancreatic neoplasm: In gastric cancer, colon cancer and pancreatic cancer, loss of the sensitivity to TGF-β inhibition has mainly been attributed to mutations in TβRII (29,30) and in downstream molecules such as Smad2 and Smad4 (31–33).